PolyPid Ltd.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 2.3
- Dividend yield
- –
About PolyPid
Surgical & Medical Instruments & Apparatus, SIC 3841
PolyPid Ltd. is a clinical-stage biopharmaceutical company focused on developing locally administered, controlled-release therapeutics to address unmet medical needs. Utilizing its proprietary PLEX drug delivery technology, the company designs treatments that continuously release therapeutic agents directly at surgical and disease sites over extended periods. Its lead investigational drug candidate, D-PLEX100, pairs PLEX with doxycycline to prevent surgical site infections, with an initial focus on patients undergoing abdominal colorectal surgeries. The company's pipeline also encompasses preclinical and early-stage development programs, including a long-acting subcutaneous delivery platform for GLP-1 receptor agonists and an intratumoral cancer therapy candidate known as OncoPLEX.
The company operates a sterile, good manufacturing practice compliant production facility located in Israel. PolyPid Ltd. conducts research and development partnerships with biotechnology entities and is based in Israel, maintaining its principal executive offices in Petach Tikva, near Tel Aviv. It also operates through corporate subsidiaries located in New Jersey and Romania.
Summary of the business section of PolyPid's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PolyPid Ltd.
- Founded
- 2008
- Headquarters
- Petach Tikva, L3
- Address
- 18 Hasivim Street 4959376
- Phone
- 972-74-7195700
- Website
- polypid.com
- Employees
- 59, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- KOST FORER GABBAY & KASIERER, Haifa, Israel
Stock & identifiers
- Ticker
- PYPD
- Exchange
- Nasdaq
- IPO date
- Jun 26, 2020
- Shares outstanding
- 18M, Dec 31, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-30 reverse, Mar 6, 2024; 1-for-30 reverse, Sep 21, 2023
- SEC CIK
- 1611842
- CUSIP
- M8001Q126
- ISIN
- USM8001Q1261
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Dikla Czaczkes Akselbrad | Chief Executive Officer, Director | 934 |
| Ori Warshavsky | Chief Operating Officer - US | 267 |
| Dalit Fellous Hazan | Deputy CEO, EVP, RD, CRA | – |
| Jonathan Missulawin | Chief Financial Officer | – |
| Joseph BenAmram | Director | – |
| Brooke Story | Director | – |
| Robert Benjamin Stein | Director | – |
| Yechezkel Barenholz | Director | 2,760 |
| Nir Dror-Darwish | Director | – |
| Itzhak Krinsky | Director | 833 |
| Yitzchak Shlomo Jacobovitz | Director | – |
Employees
Headcount reported in annual reports
“had 59 full-time employees and 3 part-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 18, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
| Mar 16, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |